share_log

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Calais Philippe

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Calais Philippe

Transcode Therapeutics | 4：持股變動聲明-董事 Calais Philippe
美股sec公告 ·  06/19 04:20
牛牛AI助理已提取核心訊息
Philippe Calais, associated with Transcode Therapeutics, Inc. [RNAZ], has been involved in a transaction dated 06/14/2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, have not been disclosed. The relationship of Philippe Calais to the issuer has not been specified in the announcement. As such, the impact of this transaction on Calais's holdings in Transcode Therapeutics remains unclear.
Philippe Calais, associated with Transcode Therapeutics, Inc. [RNAZ], has been involved in a transaction dated 06/14/2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, have not been disclosed. The relationship of Philippe Calais to the issuer has not been specified in the announcement. As such, the impact of this transaction on Calais's holdings in Transcode Therapeutics remains unclear.
與Transcode Therapeutics，Inc. [RNAZ]有關的Philippe Calais已於2024年06月14日進行了一項交易，具體交易細節包括股份數量、股份性質、交易價格以及股份總價值未被披露。Philippe Calais與發行人的關係在聲明中未被具體說明。因此，此次交易對Calais在Transcode Therapeutics的持股影響尚不明確。
與Transcode Therapeutics，Inc. [RNAZ]有關的Philippe Calais已於2024年06月14日進行了一項交易，具體交易細節包括股份數量、股份性質、交易價格以及股份總價值未被披露。Philippe Calais與發行人的關係在聲明中未被具體說明。因此，此次交易對Calais在Transcode Therapeutics的持股影響尚不明確。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。